Molsidomine decreases hyperoxia-induced lung injury in neonatal rats

BackgroundThe study's objective is to evaluate if Molsidomine (MOL), an anti-oxidant, anti-inflammatory, and anti-apoptotic drug, is effective in treating hyperoxic lung injury (HLI).MethodsThe study consisted of four groups of neonatal rats characterized as the Control, Control+MOL, HLI, HLI + MOL groups. Near the end of the study, the lung tissue of the rats were evaluated with respect to apoptosis, histopathological damage, anti-oxidant and oxidant capacity as well as degree of inflammation.ResultsCompared to the HLI group, malondialdehyde and total oxidant status levels in lung tissue were notably reduced in the HLI + MOL group. Furthermore, mean superoxide dismutase, glutathione peroxidase, and glutathione activities/levels in lung tissue were significantly higher in the HLI + MOL group as compared to the HLI group. Tumor necrosis factor-alpha and interleukin-1 beta elevations associated with hyperoxia were significantly reduced following MOL treatment. Median histopathological damage and mean alveolar macrophage numbers were found to be higher in the HLI and HLI + MOL groups when compared to the Control and Control+MOL groups. Both values were increased in the HLI group when compared to the HLI + MOL group.ConclusionsOur research is the first to demonstrate that bronchopulmonary dysplasia may be prevented through the protective characteristics of MOL, an anti-inflammatory, anti-oxidant, and anti-apoptotic drug.ImpactMolsidomine prophylaxis significantly decreased the level of oxidative stress markers.Molsidomine administration restored the activities of antioxidant enzymes.Molsidomine prophylaxis significantly reduced the levels of inflammatory cytokines.Molsidomine may provide a new and promising therapy for BPD in the future.Molsidomine prophylaxis decreased lung damage and macrophage infiltration in the tissue.

Automated summary

This study evaluated the effectiveness of Molsidomine in treating hyperoxic lung injury. The results showed that Molsidomine significantly reduced oxidative stress markers, restored antioxidant enzyme activities, and decreased inflammatory cytokine levels. It may provide a new and promising therapy for bronchopulmonary dysplasia in the future.